Oncology Corporate Profile
Mersana engineers novel drug conjugates that maximize the potential of new and established therapeutic classes. Mersana's technology harnesses the power and synergy of nanotechnology, biologics and small molecules. Mersana is advancing its own pipeline of next-generation drugs with best-in-class potential to address multiple unmet needs in oncology.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|XMT-1001||topoisomerase 1 inhibitor||2nd line metastatic Non Small Cell Lung Cancer (NSCLC)||I|
|XMT-1107||anti-angiogenic fumagillin analog||Various cancer types||I||Teva|
|Unnamed||antibody drug conjugates (ADC)||Various cancer types||Preclinical|
View additional information on product candidates here »